Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha Sells 55,000 Shares

Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $16.69, for a total value of $917,950.00. Following the completion of the sale, the chief executive officer now directly owns 276,017 shares in the company, valued at $4,606,723.73. This represents a 16.62 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Saurabh Saha also recently made the following trade(s):

• On Thursday, February 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $15.93, for a total value of $876,150.00.
• On Tuesday, January 21st, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $15.77, for a total value of $867,350.00.

Centessa Pharmaceuticals Price Performance

CNTA stock opened at $15.75 on Friday. Centessa Pharmaceuticals plc has a 52-week low of $7.75 and a 52-week high of $19.09. The stock’s fifty day simple moving average is $16.47 and its 200-day simple moving average is $16.38. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $2.08 billion, a price-to-earnings ratio of -10.29 and a beta of 1.54.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC purchased a new stake in shares of Centessa Pharmaceuticals during the third quarter worth about $2,834,000. Wellington Management Group LLP purchased a new stake in shares of Centessa Pharmaceuticals during the third quarter worth about $1,609,000. State Street Corp purchased a new stake in shares of Centessa Pharmaceuticals during the third quarter worth about $777,000. Ally Bridge Group NY LLC purchased a new stake in shares of Centessa Pharmaceuticals during the third quarter worth about $4,951,000. Finally, Lord Abbett & CO. LLC purchased a new stake in shares of Centessa Pharmaceuticals during the third quarter worth about $4,305,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on CNTA. Morgan Stanley reissued an “overweight” rating and set a $27.00 price objective on shares of Centessa Pharmaceuticals in a research note on Friday, March 7th. Guggenheim reissued a “buy” rating on shares of Centessa Pharmaceuticals in a research report on Monday, February 10th. Finally, TD Cowen assumed coverage on Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating for the company. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $26.00.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.